Background: Alzheimer’s disease is progressive degenerative disorders of the brain that begins
with memory impairment and eventually progresses to dementia, physical impairment, and
death. Tau protein belongs to the family of microtubule association protein. They are mainly
present in neurons, where they do important work; they assemble tubulin monomers into the
microtubule networks. Molecular analysis depicted that abnormal phosphorylation might be an
important event in the pathogenesis where tau is the remarkable marker of the neurodegenerative
process.
Methodology: This review article was written after collecting a huge amount of latest literature
on Tau protein inhibitors from varied pharmaceutical databases like ScienceDirect, PubMed,
Google Scholar, etc. by using specific keywords. The collected data was appropriately classified
and justified. Results: The article moreover focuses on various natural products [Plant-derived (paclitaxel,
curcumin, oleocanthal, diallyl disulfide, emodin, S-allyl cysteine, cinnamaldehyde, tanshinoneIIA,myricanone, and rosmarinic acid); Microbes-derived (adriamycin, daunorubicin,
geldanamycin, rubellin-B, rubellin-D, rubellin-E, minocycline, epithilone-D, and fulvic acid);
and Marine macroorganism-derived (peloruside-A, manzamine-A, palinurin, and
hymenialdisine)] that acts as tau-protein aggregation inhibitors.
Conclusion: This fascinating literature concluded that the low molecular-weight natural
inhibitors will positively provide research information or serve as a futuristic lead to enthusiastic
medicinal chemists and curious pharmacologists in managing Alzheimer’s disease by opening
application avenues via pharmacotherapeutic approach.
Keywords: Alzheimer's disease, Tau protein, Inhibitors, Natural, Microbes, Marines
Publication date: 15/12/2021
https://ijbpas.com/pdf/2021/December/MS_IJBPAS_2021_DEC_SPCL_1038.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.12.1038
